Donald J. Alcendor

Aug 27, 2024 | preprints.org | Donald J. Alcendor |Mohammad Tabatabai |Patricia Juárez |Derek Wilus

PreprintReviewVersion 1This version is not peer-reviewedVersion 1: Received: 26 August 2024 / Approved: 26 August 2024 / Online: 27 August 2024 (11:48:22 CEST)Alcendor, D. J.; Tabatabai, M.; Juarez, P. M.-.; Wilus, D.; Hildreth, J. E.; Juarez, P. D. HPV Vaccine Uptake in Tennessee: Implications for Improving HPV Vaccine Coverage with the Inclusion of Mid-adults. Preprints 2024, 2024081922. https://doi.org/10.20944/preprints202408.1922.v1Alcendor, D. J.; Tabatabai, M.; Juarez, P.

Jun 7, 2023 | mdpi.com | Donald J. Alcendor |Patricia Matthews-Juarez |Neely Williams |Derek Wilus

2. MethodsSurveys: Exactly 1482 surveys were administered to participants that were 18 years and older and were among predominantly medically underserved minority communities in Tennessee at pop-up vaccine events, cultural gatherings, churches and other places of worship, pediatric clinics, metro parks, back-to-school events, community-based organization events, health department events, large and small businesses, festivals, nursing homes, and assisted-living facilities.

Jun 5, 2023 | journals.plos.org | Mohammad Tabatabai |Patricia Matthews-Juarez |Donald J. Alcendor |Nader Bahri

Analysis of survival by incomeFig 1F shows the higher the income, the higher the survival probability. Only 0.3% of patients had income less than $40,000. The MST for people earning less than $40,000 was 118 months. For those 8.4% of patients who were making 40,000–55,000 dollars a year, the MST was 131 months. Patients in the income range of 55,000–75,000 constituted 47.7% of patients with the MST of 146 months. For those 43.7% of the patients making more than $75,000, the MST was 158 months.

Apr 27, 2023 | mdpi.com | Donald J. Alcendor |Patricia Matthews-Juarez |Duane L Smoot |Alexis Edwards

Abstract:The COVID-19 Omicron variant and its subvariants are now the dominant variants circulating in the US. Therefore, the original COVID-19 vaccine cannot offer full protection. Instead, vaccines that target the spike proteins of the Omicron variants are warranted. Hence, the FDA recommended the development of a bivalent booster. Unfortunately, despite the safety and immunogenicity of the Omicron bivalent boosters from Pfizer and Moderna, uptake in the US has been poor.